oxatomide has been researched along with Allergic Conjunctivitis in 2 studies
oxatomide: structure; an anti-allergic & an anti-asthmatic
oxatomide : A member of the class of benzimidazoles that is 1,3-dihydro-2H-benzimidazol-2-one substituted by a 3-[4-(diphenylmethyl)piperazin-1-yl]propyl group at position 1. It is an anti-allergic drug.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Cetirizine was significantly more effective at reducing the mean rhinorrhea score compared with oxatomide for both weeks 8 and 12 (P < 0." | 2.70 | The comparison of the efficacy and safety of cetirizine, oxatomide, ketotifen, and a placebo for the treatment of childhood perennial allergic rhinitis. ( Hsieh, JC; Lai, DS; Lee, HS; Lin, KL; Lue, KH, 2002) |
| "Oxatomide has a protective effect on clinical and cellular early phase reactions and late phase reactions (including ICAM-1 expression on epithelium) induced by allergen-specific conjunctival challenge and is safe and well tolerated." | 2.68 | Oxatomide reduces inflammatory events induced by allergen-specific conjunctival challenge. ( Benvenuti, C; Bruzzone, F; Buscaglia, S; Canonica, GW; Cavalli, E; Ciprandi, G; Pronzato, C, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lai, DS | 1 |
| Lue, KH | 1 |
| Hsieh, JC | 1 |
| Lin, KL | 1 |
| Lee, HS | 1 |
| Ciprandi, G | 1 |
| Buscaglia, S | 1 |
| Pronzato, C | 1 |
| Benvenuti, C | 1 |
| Cavalli, E | 1 |
| Bruzzone, F | 1 |
| Canonica, GW | 1 |
2 trials available for oxatomide and Allergic Conjunctivitis
| Article | Year |
|---|---|
The comparison of the efficacy and safety of cetirizine, oxatomide, ketotifen, and a placebo for the treatment of childhood perennial allergic rhinitis.
Topics: Allergens; Animals; Anti-Allergic Agents; Blood Proteins; Cetirizine; Child; Conjunctivitis, Allergi | 2002 |
Oxatomide reduces inflammatory events induced by allergen-specific conjunctival challenge.
Topics: Allergens; Anti-Allergic Agents; Conjunctivitis, Allergic; Double-Blind Method; Humans; Piperazines | 1995 |